Extraordinary medicines that advance management of gastrointestinal and infectious diseases, aimed at helping you to live an extraordinary life.
RedHill’s lean, experienced commercial team delivers the output of a larger organization, promoting FDA-approved medicines, Rebyota® and Clenpiq®
in the U.S. with agility and enterprise-level expertise.
Commercial Products:
Rebyota® (fecal microbiota, live – jslm)
prescription drug
Click here to access the full product website or Prescribing Information.
Learn More
Clenpiq® (sodium picosulfate, magnesium oxide, and anhydrous citric acid)
prescription drug
Click here to access the full product website or Prescribing Information.
Learn More
In August 2026, RedHill announced the divestment of its Talicia® business to a subsidiary of Apotex Health Corp. and in September 2026
announced
the acquisition of the exclusive global commercialization rights to Rebyota® and the exclusive U.S. commercialization rights to Clenpiq® from
Ferring Pharmaceuticals.